IMR Press / EJGO / Volume 22 / Issue 3 / pii/2001153

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer

Show Less
1 Department cif Ohstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University, School of Medicine, Ankara, Turkey
Eur. J. Gynaecol. Oncol. 2001, 22(3), 228–232;
Published: 10 June 2001

Objective: The aim of this study was to investigate the peritoneal fluid and serum lactate dehydrogenase (LDH) levels in patients with ovarian masses. Materials & Methods: Peritoneal fluid and serum lactate dehydrogenase (LDH) levels were measured in 27 patients with epithe­lial ovarian carcinoma and 38 with benign ovarian tumors. Serum and peritoneal fluid LDH levels were also compared with the levels of CA-125. Results: Both of the marker levels in ovarian cancer patients were significantly higher than those in patients with benign ovarian tumors. Serous and undifferentiated carcinomas presented higher: marker levels than endometrioid and mucinous carcinomas. High-grade, advanced stage and positive cytology were associated with higher serum and peritoneal fluid -LDH levels; there was an inefficient correlation between them but, when these two markers were used together with CA-125, sensitivity of CA-125 increased to 70%. Conclusions: In conclusion, serum LDH can be used to discriminate adnexal mass origin and peritoneal fluid LDH may have pro­gnostic value because of the strict relationship with advanced stage, poor histologic type, higher grade and positive abdominal cyto­logy. Peritoneal LDH is found to be a reliable biochemical marker related to prognosis in ovarian carcinoma patients.

Lactate dehydrogenase
Ovarian carcinoma
Back to top